2014
ERβ splice variant expression in four large cohorts of human breast cancer patient tumors
Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL. ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Research And Treatment 2014, 146: 657-667. PMID: 25007965, PMCID: PMC6939385, DOI: 10.1007/s10549-014-3050-3.Peer-Reviewed Original ResearchConceptsBreast cancerPatient tumorsERβ variantsQuantitative immunofluorescenceBreast cancer patient tumorsTriple-negative patientsBreast cancer outcomesAbsence of ERαBreast cancer biologyCancer patient tumorsBreast cancer patient samplesSplice variant expressionCancer patient samplesParaffin-embedded tissuesQIF scoresCancer outcomesPredictive biomarkersWorse outcomesEstrogen receptorLarge cohortSurvival analysisERβPatient samplesAQUA technologyVariant expressionMacrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer
How J, Brown JR, Saylor S, Rimm DL. Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochemistry And Cell Biology 2014, 142: 195-204. PMID: 24429833, PMCID: PMC4101067, DOI: 10.1007/s00418-014-1181-6.Peer-Reviewed Original ResearchMeSH KeywordsAcid PhosphataseAdenocarcinomaAdultAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorColonic NeoplasmsFemaleHumansIsoenzymesMacrophagesMaleMiddle AgedReceptors, Cell SurfaceTartrate-Resistant Acid PhosphataseTissue Array AnalysisTreatment OutcomeYoung AdultConceptsColorectal cancer patientsMacrophage expressionResistant acid phosphataseColon cancerCancer patientsTRAP expressionYale-New Haven HospitalDisease-specific deathPan-macrophage markerRisk reductionPrognostic indicatorCancer survivalColorectal adenocarcinomaM2 markersImproved outcomesTissue microarrayImmunohistochemical analysisSecond cohortSurvival analysisPatientsPotential biomarkersQuantitative immunofluorescenceCancerAcid phosphataseOld cases
2013
Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas
Viray H, Bradley WR, Schalper KA, Rimm DL, Rothberg BE. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.Peer-Reviewed Original ResearchConceptsHMB-45Primary tumorCutaneous melanomaLarge seriesMelanoma-specific survivalMelanoma primary tumorsGroup of antigensLarge tissue microarrayClinicopathologic covariatesClinicopathologic criteriaPrognostic relevanceHistopathologic profileClinicopathologic correlatesAntigen expressionClinicopathologic parametersMelanoma markersTissue microarrayPositive expressionSurvival analysisMelanomaMelanS100Melanoma cellsBivariate associationsSignificant differences
2012
Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.
Christiansen J, Bartlett J, Gustavson M, Rimm D, Robson T, Van De Velde C, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D. Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. Journal Of Clinical Oncology 2012, 30: 517-517. DOI: 10.1200/jco.2012.30.15_suppl.517.Peer-Reviewed Original ResearchEarly breast cancerBreast cancerDAB IHCHazard ratioDisease recurrenceCox proportional hazard modelingKaplan-Meier survival analysisCox proportional hazards modelC-index calculationClinical prognostic factorsProportional hazard modelingProportional hazards modelResidual riskHormone therapyIndependent predictorsPrognostic factorsPrediction of riskRisk markersClinical utilityHazards modelRecurrence riskRecurrencePathology studiesSurvival analysisMultivariate analysisEvaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.
Velcheti V, Cheng H, Yao X, Deng Y, Gettinger S, Rimm D. Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis. Journal Of Clinical Oncology 2012, 30: e21106-e21106. DOI: 10.1200/jco.2012.30.15_suppl.e21106.Peer-Reviewed Original ResearchNon-small cell lung cancerSquamous cell carcinomaSOX2 expressionWorse median overall survivalYale-New Haven HospitalMedian overall survivalMore stage IIIPatras University HospitalKaplan-Meier analysisCell lung cancerLog-rank testHigh SOX2 expressionNew Haven HospitalMore effective markersSOX2 expression levelsOverall survivalCell carcinomaLung cancerUniversity HospitalIndependent cohortKruskal-Wallis testStage IIIBetter outcomesStem cell transcription factorsSurvival analysis
2010
Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis
Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research 2010, 16: 2427-2434. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.ccr-09-2658.Peer-Reviewed Original ResearchConceptsLonger progression-free survivalNeck squamous cell cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell cancerSquamous cell carcinomaPittsburgh Medical CenterTranscription 3Early Detection Research NetworkCurative intentPrognostic roleSurgical resectionBetter prognosisSignal transducerCell cancerCell carcinomaFavorable outcomeSurvival prognosisClinicopathologic parametersMedical CenterIndependent cohortLower riskTest cohortHNSCCSurvival analysisAnalytic Variability in Immunohistochemistry Biomarker Studies
Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Analytic Variability in Immunohistochemistry Biomarker Studies. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 982-991. PMID: 20332259, PMCID: PMC3891912, DOI: 10.1158/1055-9965.epi-10-0097.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 3Cancer patientsEstrogen receptorWestern blottingBiomarker studiesEpidermal growth factor receptor 1Breast cancer patientsLung cancer patientsEpidermal growth factor receptor 3Growth factor receptor 1Factor receptor 1Growth factor receptor 3Clone 1D5Worse prognosisHigher eGFRPrognostic classificationER antibodyCancer-related biomarkersCutoff pointBT474 cellsSurvival analysisEGFR antibodyReceptor 1Receptor 3Quantitative immunofluorescence
2008
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathology 2008, 39: 1835-1843. PMID: 18715621, PMCID: PMC2632946, DOI: 10.1016/j.humpath.2008.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularConnecticutFemaleFluorescent Antibody Technique, IndirectHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesKaplan-Meier EstimateMiddle AgedNeuropilin-1Receptors, Vascular Endothelial Growth FactorSurvival RateTissue Array AnalysisVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Young AdultConceptsVascular endothelial growth factorEndothelial growth factorBreast cancerVEGFR-1Growth factorNeuropilin-1VEGFR-2Kaplan-Meier survival analysisBreast cancer tissue microarrayVascular endothelial growth factor receptorPrimary breast cancerStandard prognostic factorsEndothelial growth factor receptorPrimary breast adenocarcinomaCancer tissue microarrayTumor-specific expressionGrowth factor receptorPrognostic factorsPrognostic significancePrognostic valueWorse outcomesLarge cohortTissue microarraySurvival analysisSignificant association